Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Efficacy of RP3128 in Healthy Volunteers and Mild Asthmatics
NCT02958982Phase 2Terminated
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Nov 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing RP3128 with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events. Started Nov 2016; status: terminated.
02
Drugs
RP3128
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02958982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958982.